Vivos Therapeutics Completes Acquisition of The Sleep Center of Nevada, Secures Over $11 Million in New Financing

Reuters
14 Jun
<a href="https://laohu8.com/S/VVOS">Vivos Therapeutics</a> Completes Acquisition of The Sleep Center of Nevada, Secures Over $11 Million in New Financing

Vivos Therapeutics Inc. has announced the acquisition of Sleep Centers of Nevada $(SCN.AU)$, marking a strategic pivot towards expanding its sleep medicine and testing services. The transaction involved a $6 million cash payment and $1.5 million in Vivos common stock to SCN. An additional $1.5 million in Vivos common stock could be awarded if SCN achieves certain financial milestones. The acquisition is financed through a senior term loan from Streeterville Capital LLC and a private placement investment by New Seneca Partners. Vivos expects this acquisition to enhance its diagnostic and treatment revenues, aiming for cash flow positivity as SCN locations integrate Vivos treatments. CEO Kirk Huntsman expressed excitement about the acquisition, noting that SCN patient bookings are already fully scheduled.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-015115), on June 13, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10